BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 12928123)

  • 1. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
    Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
    Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
    Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
    Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
    Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
    Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).
    Grigorescu A; Ciuleanu T; Firoiu E; Muresan DR; Teodorescu G; Basson BR
    Lung Cancer; 2007 Aug; 57(2):168-74. PubMed ID: 17467848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
    Treat JA; Gonin R; Socinski MA; Edelman MJ; Catalano RB; Marinucci DM; Ansari R; Gillenwater HH; Rowland KM; Comis RL; Obasaju CK; Belani CP;
    Ann Oncol; 2010 Mar; 21(3):540-547. PubMed ID: 19833819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
    Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Matano E; Boni C; Marangolo M; Failla G; Altavilla G; Adamo V; Ceribelli A; Clerici M; Di Costanzo F; Frontini L; Tonato M;
    J Clin Oncol; 2002 Nov; 20(21):4285-91. PubMed ID: 12409326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
    Grigorescu AC; Draghici IN; Nitipir C; Gutulescu N; Corlan E
    Lung Cancer; 2002 Jul; 37(1):9-14. PubMed ID: 12057861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
    Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
    J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
    Shi X; Yu XM; Zhang YP; Zhao J
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):221-4. PubMed ID: 23880005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
    Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
    Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L
    Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
    Langer C; Li S; Schiller J; Tester W; Rapoport BL; Johnson DH;
    J Clin Oncol; 2007 Feb; 25(4):418-23. PubMed ID: 17264337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
    Zwitter M; Kovac V; Smrdel U; Vrankar M; Zadnik V
    J Thorac Oncol; 2009 Sep; 4(9):1148-55. PubMed ID: 19546818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer.
    Hasegawa Y; Miura D; Kitamura C; Suzuki T; Kobayashi K; Sato N
    Chemotherapy; 2013; 59(5):346-53. PubMed ID: 24821009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
    Thomas P; Robinet G; Gouva S; Fournel P; Léna H; Le Caer H; Perol M; Berard H; Bombaron P; Vergnenegre A; Kleisbauer JP;
    Lung Cancer; 2006 Jan; 51(1):105-14. PubMed ID: 16310886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
    Rosell R; Tonato M; Sandler A
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):27-34. PubMed ID: 9728582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
    Treat J; Edelman MJ; Belani CP; Socinski MA; Monberg MJ; Chen R; Obasaju CK;
    Lung Cancer; 2010 Dec; 70(3):340-6. PubMed ID: 20347506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
    Fukumoto SI; Oizumi S; Harada M; Sukoh N; Nakano K; Fuke S; Sakakibara-Konishi J; Takamura K; Ito K; Fujita Y; Nishigaki Y; Harada T; Akie K; Kinoshita I; Amano T; Isobe H; Dosaka-Akita H; Nishimura M;
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):117-127. PubMed ID: 32564128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.